UNSPSC 51273939: Epinephrine/lidocaine/povidone/sodium chloride

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.

UNSPSC 51273939 Epinephrine/lidocaine/povidone/sodium chloride is a Commodity code covering emergency medical pharmaceutical compounds and related injectable medications. State and local governments procure these products primarily through county health departments, state health and human services agencies, and multistate cooperative purchasing vehicles to support emergency medical response, community health initiatives, and pharmacy benefit programs. Recent solicitations show demand for naloxone and injectable pharmaceutical products with specific NDC requirements, compliance with FDA Good Manufacturing Practices and Drug Supply Chain Security Act standards, and delivery through authorized wholesale channels. Issuing bodies include county departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple states and localities (Minnesota Multistate Cooperative Purchasing Alliance administering contracts across state and local government facilities in participating jurisdictions including Oregon).

Geographic activity spans Florida, Texas, Minnesota, and Oregon based on recent opportunities. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, with bids due July 26, 2023, on a two-year term with one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit managers and wholesalers. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 through MMCAP in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, establishing contracts effective July 1, 2026, across participating state and local government facilities; awards are weighted 75 percent on price competitiveness, with vendors required to maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and to pay a 3 percent administrative fee.